Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells

Maddalena Vagliani, Monica Rodolfo, Federica Cavallo, Mariella Parenza, Cecilia Melani, Giorgio Parmiani, Guido Forni, Mario P. Colombo

Research output: Contribution to journalArticle

Abstract

The purpose of these studies was to determine whether systemic administration of recombinant interleukin 12 (rIL-12) is able to potentiate an initial, but insufficient T-cell antitumor response. Mice challenged with carcinoma cells engineered to release interleukin 2 (IL-2) and displaying such a response received single or multiple i.p. injections of rIL-12. This combination of systemic rIL-12 and local IL-2 increased the percentage of mice that rejected two different IL-2 gene-transduced tumors. In another set of experiments more closely resembling a clinical situation, IL-2 gene- transduced tumors were used as vaccines in an attempt to cure mice hearing wild-type parental tumors. The combination of these vaccines with systemic rIL-12 cured mice more effectively than rIL-12 and IL-2 gene-transduced tumor vaccines alone.

Original languageEnglish
Pages (from-to)467-470
Number of pages4
JournalCancer Research
Volume56
Issue number3
Publication statusPublished - Feb 1 1996

Fingerprint

Interleukin-12
Interleukin-2
Vaccines
Neoplasms
Genes
Combined Vaccines
Cancer Vaccines
Hearing
Carcinoma
T-Lymphocytes
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. / Vagliani, Maddalena; Rodolfo, Monica; Cavallo, Federica; Parenza, Mariella; Melani, Cecilia; Parmiani, Giorgio; Forni, Guido; Colombo, Mario P.

In: Cancer Research, Vol. 56, No. 3, 01.02.1996, p. 467-470.

Research output: Contribution to journalArticle

Vagliani, Maddalena ; Rodolfo, Monica ; Cavallo, Federica ; Parenza, Mariella ; Melani, Cecilia ; Parmiani, Giorgio ; Forni, Guido ; Colombo, Mario P. / Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. In: Cancer Research. 1996 ; Vol. 56, No. 3. pp. 467-470.
@article{979e3ef6edd74ecda56dc1068d1b3bae,
title = "Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells",
abstract = "The purpose of these studies was to determine whether systemic administration of recombinant interleukin 12 (rIL-12) is able to potentiate an initial, but insufficient T-cell antitumor response. Mice challenged with carcinoma cells engineered to release interleukin 2 (IL-2) and displaying such a response received single or multiple i.p. injections of rIL-12. This combination of systemic rIL-12 and local IL-2 increased the percentage of mice that rejected two different IL-2 gene-transduced tumors. In another set of experiments more closely resembling a clinical situation, IL-2 gene- transduced tumors were used as vaccines in an attempt to cure mice hearing wild-type parental tumors. The combination of these vaccines with systemic rIL-12 cured mice more effectively than rIL-12 and IL-2 gene-transduced tumor vaccines alone.",
author = "Maddalena Vagliani and Monica Rodolfo and Federica Cavallo and Mariella Parenza and Cecilia Melani and Giorgio Parmiani and Guido Forni and Colombo, {Mario P.}",
year = "1996",
month = "2",
day = "1",
language = "English",
volume = "56",
pages = "467--470",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells

AU - Vagliani, Maddalena

AU - Rodolfo, Monica

AU - Cavallo, Federica

AU - Parenza, Mariella

AU - Melani, Cecilia

AU - Parmiani, Giorgio

AU - Forni, Guido

AU - Colombo, Mario P.

PY - 1996/2/1

Y1 - 1996/2/1

N2 - The purpose of these studies was to determine whether systemic administration of recombinant interleukin 12 (rIL-12) is able to potentiate an initial, but insufficient T-cell antitumor response. Mice challenged with carcinoma cells engineered to release interleukin 2 (IL-2) and displaying such a response received single or multiple i.p. injections of rIL-12. This combination of systemic rIL-12 and local IL-2 increased the percentage of mice that rejected two different IL-2 gene-transduced tumors. In another set of experiments more closely resembling a clinical situation, IL-2 gene- transduced tumors were used as vaccines in an attempt to cure mice hearing wild-type parental tumors. The combination of these vaccines with systemic rIL-12 cured mice more effectively than rIL-12 and IL-2 gene-transduced tumor vaccines alone.

AB - The purpose of these studies was to determine whether systemic administration of recombinant interleukin 12 (rIL-12) is able to potentiate an initial, but insufficient T-cell antitumor response. Mice challenged with carcinoma cells engineered to release interleukin 2 (IL-2) and displaying such a response received single or multiple i.p. injections of rIL-12. This combination of systemic rIL-12 and local IL-2 increased the percentage of mice that rejected two different IL-2 gene-transduced tumors. In another set of experiments more closely resembling a clinical situation, IL-2 gene- transduced tumors were used as vaccines in an attempt to cure mice hearing wild-type parental tumors. The combination of these vaccines with systemic rIL-12 cured mice more effectively than rIL-12 and IL-2 gene-transduced tumor vaccines alone.

UR - http://www.scopus.com/inward/record.url?scp=0030066799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030066799&partnerID=8YFLogxK

M3 - Article

C2 - 8564954

AN - SCOPUS:0030066799

VL - 56

SP - 467

EP - 470

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 3

ER -